Biotron Limited (BITRF) Research

Biotron Limited is an Australian biotechnology firm focused on the development and market introduction of small-molecule compounds designed to combat various viral infections. The company's primary antiviral agent, BIT225, is currently undergoing Phase II clinical trials to assess its efficacy against SARS-CoV-2, HIV-1, and hepatitis C virus infections. Founded in 1999, Biotron Limited's main offices are situated in Sydney, Australia.

Market snapshot

Symbol
BITRF
Price
$0.00
Day change
0.00%
Market cap
$4.1M
P/E ratio
-1.94x
52-week range
0.0011-0.10144
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Bangi Inc. (BNGI)
  • Biophytis S.A. (BPTSY)
  • Dynatronics Corporation (DYNT)
  • Global Roundtable Corporation (GRCU)
  • MultiCell Technologies, Inc. (MCET)
  • Mednow Inc. (MDNWF)
  • Pathfinder Cell Therapy, Inc. (PFND)
  • Therapeutic Solutions International, Inc. (TSOI)

Open Biotron Limited (BITRF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.